Breast Cancer News
Follow
Find
55.6K views | +16 today
Latest News, Research, and Articles of Interest
Curated by Susan Zager
Your new post is loading...
Your new post is loading...
Scooped by Susan Zager
Scoop.it!

Galena Biopharma’s (NASDAQ:GALE) Breast Cancer Vaccine Offers New Hope

Galena Biopharma’s (NASDAQ:GALE) Breast Cancer Vaccine Offers New Hope | Breast Cancer News | Scoop.it
By Amy Baldwin Galena Biopharma, Inc. (NASDAQ:GALE) is working on its breast cancer vaccine, NeuVax, which has entered into Phase III trials.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

CONFIRM Trial: Confirmation of Clinical Experience that High... : Oncology Times

CONFIRM Trial: Confirmation of Clinical Experience that High... : Oncology Times | Breast Cancer News | Scoop.it

"n an interview after the presentation, moderator Kathy S. Albain, MD, Professor of Medicine in the Division of Hematology/Oncology at Loyola University Medical Center, said the report would probably not affect clinical practice very much “because we've already been pretty confident to switch the dose to 500 mg. But it was important to show to a large audience that the initial report of a benefit to the double-dose state was robust, and didn't go away.”"

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

ATLAS Trial: ‘Carryover’ Effect of Tamoxifen Extends to 15 Y... : Oncology Times

ATLAS Trial: ‘Carryover’ Effect of Tamoxifen Extends to 15 Y... : Oncology Times | Breast Cancer News | Scoop.it

"Barlow said that unfortunately, ATLAS can't be directly compared with the randomized, Phase III MA.17 trial, which found that five years of letrozole after discontinuation of tamoxifen extended disease-free survival and, for some patients, overall survival, due to different outcome measures and duration of follow-up. “But in general, the disease-free survival and recurrence rates [of MA.17] would tend to favor switching to the aromatase inhibitor letrozole rather than continuing with tamoxifen,” he said."

Susan Zager's insight:

This is great analysis of the ATLAS trial showing it's flaws and strengths.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Key Takeaways Related to HER2 Therapy : Oncology Times

Key Takeaways Related to HER2 Therapy : Oncology Times | Breast Cancer News | Scoop.it

"The clinical options available to treat HER2-positive breast cancer, in both the early and late stage setting, have been informed by the results of large, pivotal clinical trials. These trials have not only provided guidance to the optimal way to utilize adjuvant trastuzumab, but also expanded therapeutic options with new agents available for treatment of metastatic, HER2-positive breast cancer. The 2012 San Antonio Breast Cancer Symposium highlighted several important presentations that add to our body of knowledge and re-affirm the impact of anti-HER2 agents."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Let's talk about sex ... and cancer

Let's talk about sex ... and cancer | Breast Cancer News | Scoop.it
Michelle was prepared to lose her hair, deal with nausea, even die. But when she survived cancer she wasn't prepared for what came next.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New approach mimicking the body's natural defenses could help treat a therapy-resistant breast cancer

New approach mimicking the body's natural defenses could help treat a therapy-resistant breast cancer | Breast Cancer News | Scoop.it
A new combination of antibodies was found to be effective in mice against triple-negative breast cancer.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

FDA: First Generic Version of Cancer Drug Doxil Approved - Chemotherapy Advisor

FDA: First Generic Version of Cancer Drug Doxil Approved - Chemotherapy Advisor | Breast Cancer News | Scoop.it
The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages of the brand-name medication.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

NORWESCAP receives $20,000 grant for breast cancer program

NORWESCAP receives $20,000 grant for breast cancer program | Breast Cancer News | Scoop.it
The Avon Breast Health Outreach Program has awarded a $20,000 one-year grant to the Northwest New Jersey Community Action Partnership, Inc. (NORWESCAP) to increase awareness of the life-saving benefits of early detection of breast cancer.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Young Asian/Pacific Islander Women in Calif. Face Higher Breast Cancer Risk | Center for Advancing Health

Young Asian/Pacific Islander Women in Calif. Face Higher Breast Cancer Risk | Center for Advancing Health | Breast Cancer News | Scoop.it

"Young Asian and Pacific Islander women born in California have higher risks of breast cancer than young white women, and some groups, including Filipinas, might have higher risks than African-Americans, according to a new study that challenges the perception that these women are at a much lower risk of breast cancer than white women."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Black and Hispanic Women With Breast Cancer Face Treatment Delays | Center for Advancing Health

Black and Hispanic Women With Breast Cancer Face Treatment Delays | Center for Advancing Health | Breast Cancer News | Scoop.it

"Researchers found that 62.4 percent of African-American women and 59.3 percent of Hispanic women received a diagnosis of stage II or stage III breast cancer compared with 48.9 percent of white women, and past research has linked diagnosis at advanced stages to lower survival rates. Delays in treatment were apparent in the new study, as African-American and Hispanic women had higher risks of 30-, 60- and 90-day delays compared to white women."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Routine Follow-up Mammography Benefits Breast Cancer Survivors | Center for Advancing Health

Routine Follow-up Mammography Benefits Breast Cancer Survivors | Center for Advancing Health | Breast Cancer News | Scoop.it

"After breast cancer surgery, a follow-up regimen that includes regular mammograms offers a survival benefit over a follow-up regimen that does not include mammograms, according to a new systematic review."

more...
Heather Swift's curator insight, February 8, 2013 12:27 PM

"After breast cancer surgery, a follow-up regimen that includes regular mammograms offers a survival benefit over a follow-up regimen that does not include mammograms, according to a new systematic review."

Scooped by Susan Zager
Scoop.it!

Main culprit behind breast cancers discovered

Main culprit behind breast cancers discovered | Breast Cancer News | Scoop.it
London, February 7 (ANI): University of Minnesota researchers have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

How one mom with metastatic cancer talks to her children about cancer

How one mom with metastatic cancer talks to her children about cancer | Breast Cancer News | Scoop.it
My friend Lisa Adams, who coached me through so much of my treatment for breast cancer, recently learned that her breast cancer returned as metastatic disease.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

MUSINGS OF A CANCER DOCTOR: Taking Off from San Antonio : Oncology Times

MUSINGS OF A CANCER DOCTOR: Taking Off from San Antonio : Oncology Times | Breast Cancer News | Scoop.it

"I found this study interesting for what it points to in our future. If one has to screen 50 patients to find one with a HER2 mutation, then one has to screen 500 patients to perform a 10-patient pilot therapeutic trial. We will see this again and again in the genomic era, where raw driver mutations are routine, and it will force us to change the way we study the disease. A consortium of investigators is now actively screening patients for HER2-activating mutations for entry into a neratinib trial."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

BOLERO-2 Study: Everolimus-Exemestane Overcomes Al Resistanc... : Oncology Times

BOLERO-2 Study: Everolimus-Exemestane Overcomes Al Resistanc... : Oncology Times | Breast Cancer News | Scoop.it

"

The doubling of progression-free survival in BOLERO-2 shows it is one of the most positive studies—“and this just on our first try, so now we can refine things tremendously,” he said, adding that an analysis of gene sequencing from BOLERO-2 will be presented this spring at the American Association for Cancer Research Annual Meeting.

“Now imagine if we can begin to refine the whole approach by trying to identify who responds better,” he said."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Key Takeaways about Hormonal Therapy for Metastatic Breast C... : Oncology Times

Key Takeaways about Hormonal Therapy for Metastatic Breast C... : Oncology Times | Breast Cancer News | Scoop.it

"The sequential use of endocrine agents has been the mainstay therapeutic approach for patients with hormone-receptor (HR) metastatic breast cancer for decades, resulting in median survivals in the range of four years. However, eventually resistance to endocrine therapies occurs in all patients with HR-positive metastatic breast cancer. The approval of everolimus for metastatic breast cancer, resistant to non-steroidal aromatase inhibitors, represents a new era in the treatment of this disease, and demonstrates that targeting growth factor pathways appears to reverse resistance to endocrine therapies. An improved understanding of the mechanisms underlying endocrine-resistance should yield new therapeutic approaches and improve outcomes for patients with HR-positive metastatic breast cancer. However, some approaches appear to be more fruitful than others."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Key Takeaways about Metastatic Triple-Negative Breast Cancer : Oncology Times

Key Takeaways about Metastatic Triple-Negative Breast Cancer : Oncology Times | Breast Cancer News | Scoop.it

"Triple-negative breast cancer has recently received much media attention with the publication of the Cancer Genome study in Nature with its molecular characterization and relation to ovarian cancer (2012;490:61-70). At this year's San Antonio Breast Cancer Symposium, ER-positive breast cancer still took front stage, where the most talked about and potentially practice-changing news was the findings from the ATLAS study of adjuvant tamoxifen and updated results for large trials focusing on HER2 disease. As for triple-negative metastatic breast cancer (TN MBC), though, unfortunately there was no major practice-changing news. Rather, the spotlight was on the continued quest to better understand the molecular driver pathways of triple-negative disease and identify therapeutic targets."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Guidelines updated for young cancer survivors fertility followup

Guidelines updated for young cancer survivors fertility followup | Breast Cancer News | Scoop.it
Current recommendations for the assessment and management of female reproductive complications following treatment of cancers in childhood, adolescence, and young adulthood have been updated.
more...
Heather Swift's curator insight, February 8, 2013 12:24 PM

Current recommendations for the assessment and management of female reproductive complications following treatment of cancers in childhood, adolescence, and young adulthood have been updated.

Susan Zager's comment, February 8, 2013 1:13 PM
There really ought to always be a follow up about fertility as well as physical complications as a result of breast cancer treatment.
Scooped by Susan Zager
Scoop.it!

Triple-negative breast cancer subtypes identified using microRNA

Triple-negative breast cancer subtypes identified using microRNA | Breast Cancer News | Scoop.it
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Breast cancer diagnostic errors major cause of malpractice suits

Breast cancer diagnostic errors major cause of malpractice suits | Breast Cancer News | Scoop.it
Interpretative errors more common in radiologist malpractice suits versus communicative/procedural.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Researchers Gather To Discuss Therapy Alternative For Breast Cancer

Researchers Gather To Discuss Therapy Alternative For Breast Cancer | Breast Cancer News | Scoop.it
Proton therapy evaluated as a treatment optionRadiation oncologists from some of the country's leading cancer centers will meet in Phoenix later this week to discuss the appropriat
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Prognostic and Predictive Value of Tumor VEGF Gene Amplification in Metastatic Breast Cancer Treated With Paclitaxel With and Without Bevacizumab; Results From ECOG 2100 Trial - OncologySTAT

Prognostic and Predictive Value of Tumor VEGF Gene Amplification in Metastatic Breast Cancer Treated With Paclitaxel With and Without Bevacizumab; Results From ECOG 2100 Trial - OncologySTAT | Breast Cancer News | Scoop.it

"A retrospective analysis of data from a phase III study showed that amplification of VEGFA was associated with poor survival outcomes in patients with metastatic breast cancer who received bevacizumab with paclitaxel, compared with those who did not have amplified VEGFA."

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Minnesota writer, actress Gail Frazer dies of breast cancer at 66

Minnesota writer, actress Gail Frazer dies of breast cancer at 66 | Breast Cancer News | Scoop.it
Gail Frazer and Mary Monica Pulver Kuhfeld were excited about the recent discovery of the bones of Richard III.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Breast Cancer Patients More Satisfied When Specialists Share Care Management | Center for Advancing Health

Breast Cancer Patients More Satisfied When Specialists Share Care Management | Center for Advancing Health | Breast Cancer News | Scoop.it

"Patients with breast cancer report greater satisfaction with care when their cancer doctor co-manages their care with other specialists. However, some specialists are more likely than others to share decision-making with other physicians, finds a new study in Health Services Research."

more...
Heather Swift's curator insight, February 8, 2013 12:28 PM

"Patients with breast cancer report greater satisfaction with care when their cancer doctor co-manages their care with other specialists. However, some specialists are more likely than others to share decision-making with other physicians, finds a new study in Health Services Research."

Scooped by Susan Zager
Scoop.it!

Even With Insurance, Racial Disparities in Breast Cancer Treatment Persist | Center for Advancing Health

Even With Insurance, Racial Disparities in Breast Cancer Treatment Persist | Center for Advancing Health | Breast Cancer News | Scoop.it

"More White women are diagnosed with breast cancer than Black women, yet Black women with breast cancer have a higher mortality rate. One potential explanation for this disparity is delayed treatment, perhaps due to differences in socioeconomic status and access to care. However, a new study in Ethnicity & Disease finds that some disparities persist even when Black and White patients have the same Medicaid health insurance and similar economic status. "

more...
No comment yet.